Inclusion Criteria:  Patients aged 18 years or older WHO performance status 0 or 1; Patient eligible for SRT after a multidisciplinary committee decision; Patient with BMs from radioresistant cancer (renal cell carcinoma, sarcoma, melanoma) is eligible Patient having up to 5 BM of solid tumours with an histologically proven diagnoses; patients who have had a metastasectomy and having 1 to 4 BM lesions is eligible (ANOCEF recommendations); post-operative cavity must be treated by radiosurgery according to local procedures with respect of non-inclusion criteria* (cavity will not be analyzed for efficacy) Each targeted brain lesion(s) for SRT measuring at least 10 mm and no more than 25 mm in diameter; patients whose synchronous 1-5 BM include 4 lesions measuring less than 10 mm and/or more than 25 mm will be eligible (these lesions will be treated at the discretion of the investigator). Max cumulative GTV of 30cm3 Patient with an extra-cranial complete response disease under systemic therapy (chemotherapy or targeted therapy); Patient with an extra-cranial partial response or stable disease for more than three months under systemic therapy (chemotherapy or targeted therapy); Absence of bleeding BM or meningeal carcinomatosis; Symptomatic BM are allowed  DS-GPA score 0:  Renal cancer: DS-GPA 2,5 or more Breast cancer: DS-GPA 2,5 or more Melanoma: DSGPA 3 or more Gastro-Instestinal (GI) cancer: DSGPA 3 or more Adenocarcinoma lung cancer: DS-GPA 2 or more (DS-GPAmol) Squamous lung cancer : DS-GPA 2,5 or more (DS-GPAmol) Patient with no concomitant systemic treatment; in case of ongoing systemic treatment, wash out period of 3-7 days before and after SRT, depending of drug and at the discretion of investigator; Patient sufficiently cooperating to perform the treatment with the use of a thermoformed mask; Patient whose neuropsychological abilities allow to follow the requirements of the protocol; Signed informed consent form Patients affiliated to the social security system  Exclusion Criteria:  Patients with small cell lung cancer, germ-cell tumours, lymphoma, leukemia and multiple myeloma; Patients with metastases in the brain stem, or within 1 cm of the optic apparatus; Patients with an associated neurodegenerative disease; Any symptoms not attributable to BM or cancer disease requiring long term corticosteroid use (regardless of dose); Contraindication to perform the brain MRI or gadolinium or iodinated contrast; Patients with previous brain stereotactic irradiation Whole brain irradiation history; Progressive extra-cranial disease; Haemorrhagic metastasis; Ongoing anti angiogenic treatment (treatment should be held 3-7 days before irradiation and re-initiated 3-7 days after irradiation for patient to be eligible); Patients with too close brain lesions for whom a treatment plan on one target metastasis delivers a dose > 5 Gy on other concomitant metastasis ; Patient deprived of liberty or under guardianship; Known pregnancy or breastfeeding Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study; Participation in a therapeutic trial for less than 30 days. Current or past history of second neoplasm diagnosed within the last 5 years Patient deprived of freedom or under guardianship